Welcome to our dedicated page for Biomea Fusion SEC filings (Ticker: BMEA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biomea Fusion, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations, clinical-program updates, and capital-structure information for its common stock.
The company’s proxy materials cover annual meeting voting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. These filings frame Biomea’s disclosures around icovamenib, BMF-650, pipeline development, financing needs, governance, and public-company reporting obligations.
Biomea Fusion, Inc. director Elizabeth Faust received a grant of stock options covering 196,299 shares of common stock at an exercise price of $1.15 per share. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, contingent on her continued service. Following this grant, she holds 196,299 derivative securities directly.
Biomea Fusion, Inc. director Eric Aguiar received a grant of stock options covering 196,299 shares of common stock. The options have an exercise price of $1.15 per share and expire on June 9, 2036.
The options were granted as compensation rather than an open-market purchase. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, provided Aguiar continues to serve the company through that vesting date.
Biomea Fusion, Inc. director Ray Sumita received a stock option grant covering 196,299 shares of common stock. The option has an exercise price of $1.1500 per share and expires on June 9, 2036. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, subject to Sumita’s continued service. Following this compensation-related award, Sumita holds 196,299 derivative securities directly, with no open-market buying or selling reported.
Biomea Fusion, Inc. director Julianne Averill reported receiving a stock option grant under the company’s equity plan. The option covers 173,711 shares of Common Stock at an exercise price of $1.15 per share and expires on June 9, 2036.
The filing states this is a compensation-related award, not an open-market purchase or sale. According to the vesting terms, all underlying shares will vest in full on the earlier of one year from the grant date or immediately before the next annual stockholder meeting, provided she continues serving the company through that date.
Biomea Fusion, Inc. reported the results of its Annual Meeting of Stockholders held on June 10, 2026. Holders of 72,299,440 common shares were entitled to vote, and 43,924,456 shares were present or represented by proxy.
Stockholders elected Rainer (Ramses) Erdtmann and Eric Aguiar as Class II directors to serve until the 2029 Annual Meeting or until successors are elected and qualified. Their elections included broker non-votes totaling 20,107,625 shares.
Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 40,209,966 votes for, 3,561,734 against, and 152,756 abstentions.
Biomea Fusion, Inc. reported a net loss of $12.4 million for the quarter ended March 31, 2026, narrower than the $29.3 million loss a year earlier, as it sharply reduced research and development and administrative spending while remaining pre‑revenue.
Quarter-end cash, cash equivalents and restricted cash totaled $45.1 million, with management stating this is expected to fund operations only into the first quarter of 2027, creating substantial doubt about the company’s ability to continue as a going concern without additional financing. The company focuses on clinical-stage diabetes and obesity programs, including Phase II trials of icovamenib in type 2 diabetes and a Phase I trial of BMF-650 in obesity, and ended the quarter with 72.3 million common shares outstanding and a $461.5 million accumulated deficit.
Biomea Fusion reported first quarter 2026 results and clinical progress in its diabetes and obesity programs. The company is advancing icovamenib, a potential first-in-class oral menin inhibitor for type 1 and type 2 diabetes, and BMF-650, an oral GLP-1 RA candidate for obesity.
Chronic toxicology studies for icovamenib in two species were successfully completed, supporting chronic clinical dosing. In the Phase II COVALENT-112 trial in type 1 diabetes, patients on 200 mg icovamenib showed a 52% increase from baseline in mean C-peptide AUC at Week 12 and mean C-peptide AUC was largely preserved through Week 52 with about a 7% decline. Two Phase II T2D trials (COVALENT-211 and -212) and the Phase I GLP-131 obesity study are ongoing, with 26-week T2D topline data expected in the fourth quarter of 2026 and initial 28-day obesity data in the second quarter of 2026.
Financially, Biomea ended March 31, 2026 with $45.1 million in cash, cash equivalents and restricted cash and projects cash runway into the first quarter of 2027. Net loss narrowed to $12.4 million from $29.3 million a year earlier as R&D expenses fell to $9.1 million from $22.9 million and G&A expenses declined to $3.7 million from $6.8 million, reflecting lower external costs and headcount.
Biomea Fusion, Inc. reported topline 52‑week results from its Phase 2 COVALENT‑112 trial of icovamenib in adults with type 1 diabetes. In patients diagnosed within 0–3 years and treated with 200 mg once daily for 12 weeks, mean C‑peptide area under the curve increased by 52% at Week 12 (p<0.001; n=5), indicating a statistically robust rise in endogenous insulin secretion.
After stopping treatment, mean C‑peptide AUC in this cohort showed only about a 7% decline from baseline by Week 52, suggesting durability of effect. Patients with 3–15 years’ disease duration generally preserved C‑peptide through Week 52. Icovamenib was generally well tolerated over the 52‑week observation period, with no new or unexpected safety signals. The company plans a new Phase 2 trial in patients diagnosed within 3 years, testing extended 200 mg dosing for up to 6 or 12 months and exploring combination with an immunosuppressive JAK inhibitor at four U.S. diabetes centers.
Biomea Fusion, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 10, 2026. Holders of its 72,299,440 outstanding common shares as of April 13, 2026 may participate online and vote.
Stockholders are being asked to elect two Class II directors, co‑founder and President/COO Rainer (Ramses) Erdtmann and Lead Independent Director Eric Aguiar, M.D., to serve until the 2029 meeting, and to ratify Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026. Deloitte billed audit fees of $1,160,774 in 2025 and $1,121,813 in 2024.
The proxy details board and committee structure, director independence, and compensation. Non‑employee directors receive cash retainers plus stock option grants sized to Black‑Scholes values of $360,000 at initial appointment and $185,000 annually. In 2025, Interim CEO Michael J.M. Hitchcock, Ph.D., earned salary of $486,739, a bonus of $220,076 and option awards valued at $1,848,576, while President/COO Erdtmann received salary of $489,604, a $146,881 bonus and option awards valued at $1,574,199. The company remains an “emerging growth company,” using scaled disclosure and reduced advisory vote requirements.